

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA

**Obinutuzumab in combination with chlorambucil for untreated
chronic lymphocytic leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No potential equality issues were identified during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No potential equality issues were raised in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for

the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No equalities issues were identified.

Approved by Programme/ Associate Director (name):

Meindert Boysen/Frances Sutcliffe.....

Date: 24 September 2014

Consultation 2

1. Have any additional potential equality issues been raised during the

consultation, and, if so, how has the Committee addressed these?

One consultee commented in their consultation response that failure to consider the population who cannot have fludarabine as 2 separate groups (those who can have bendamustine and those who cannot) may be interpreted as discriminatory. This is because people who cannot have bendamustine would not have access to alternative effective treatments if obinutuzumab was not recommended. The Committee decided that this was not an equality issue under the equality legislation and therefore its recommendations did not lead to discrimination and it did not need to add to, or change its recommendations.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 4.22.

Approved by Associate Director (name): Frances Sutcliffe.....

Date: 24 11 2014

Final Appraisal Determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No other potential equality issues were identified during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable – the recommendations did not change after consultation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable – the recommendations did not change after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable – the recommendations did not change after consultation.

5. Have the Committee's considerations of equality issues been

described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues have been described in section 4.19 of the FAD.

Approved by Programme Director (name): ...Meindert Boysen.....

Date: 03 03 2015